RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients

Overview

The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC) injection of RM-493, in subjects with POMC (propiomelanocortin) or other related rare genetic mutations, on body weight, metabolic function and blood pressure. Patients who respond during the initial 84 days of treatment can enter into long-term (2-year) extensions. The study drug (RM-493) will be administered in an unblinded fashion.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2018

Interventions

  • Drug: RM-493

Arms, Groups and Cohorts

  • Experimental: RM-493 Once Daily
    • Dose once daily in the morning

Clinical Trial Outcome Measures

Primary Measures

  • Effect of RM-493 on Body weight
    • Time Frame: Day 1 through Day 84
    • Change of body weight after Treatment with RM-493.

Secondary Measures

  • Effect of RM-493 on metabolic serum parameters
    • Time Frame: Day 1 through Day 84
    • Measurement of the effect of RM-493 on metabolic serum parameters as measured by blood test.
  • Effect of RM-493 on blood pressure
    • Time Frame: Day 1 through Day 84
    • Measurement of the effect of RM-493 on blood pressure by daily blood pressure measurements.
  • Effect of RM-493 on hunger
    • Time Frame: Day 1 through Day 84
    • Measurement of the effect of RM-493 on hunger as measured by the Global Hunger Scale
  • Effect of RM-493 on body composition/Energy expenditure
    • Time Frame: Day 1 through Day 84
    • Measurement of the effect of RM-493 on body composition/Energy expenditure
  • Effect of RM-493 on weight loss after treatment continuation of 2 years
    • Time Frame: Day 1 through Day 730
    • Measurement of the effect of RM-493 on weight loss after treatment continuation of 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • Written informed consent – Homozygous or compound heterozygous (different gene mutation on both alleles) POMC, LEPR or PCSK1 gene mutation – Obesity (BMI > 30 kg/m2; + 2 BMI SDS) – No other therapeutic option, which might cure the patient (e.g. bariatric surgery (see chapter 8)) – Negative Pregnancy test – Highly effective contraception in women (defined as pearl index < 1), if necessary also for partners of test persons) – No participation in other clinical trials according to AMG (Arzneimittelgesetz) (2 months before and after) at the time of this trial – Normal or minimally elevated blood pressure (measured in 24RR monitoring or similar methods) according the guidelines of the ESH (European Society of Hypertension) and Deutsche Hochdruckliga: systolic > 159 mmHg/diastolic 99 mmHg – sufficient kidney and liver function (Creatinine, ALT, AST) – normal values Alanine-Aminotransferase (ALT) (female): < 31 U/l – normal values Alanine-Aminotransferase (ALT) (male): < 41 U/l – normal values Aspartate-Aminotransferase (AST) (female > 17 years): < 35 U/l; (female < 17 years): 16- 46 U/l – normal values Aspartate-Aminotransferase (AST) (male > 17 years): < 50 U/l; (male < 17 years): 16-46 U/l – normal values bilirubins (male and female) up to 1,2 mg/dl – normal values Creatinine (female > 15 years): 0,51-0,95 mg/dl) ; (female < 15 years): 0,46-0,77 mg/dl – normal values Creatinine (male > 15 years): 0,67 – 1,17 mg/dl) ; (male < 15 years): 0,46-0,77 mg/dl Exclusion Criteria:

  • Pregnancy or Breastfeeding – All contraindications against study medication (including auxiliary substances) – Interactions with study medication – Participation of the patient in a clinical study within the last 2 months – Intolerance against albumin – Concomitant diseases, impaired organ functions, except for known, concurrent GI disorders or other clinical findings expected in PCSK1 or LEPR gene disorders – Renal insufficiency (Creatinine > 0,95 mg/dl (female), > 1,17 mg/dl (male)) – Impaired liver function (Bilirubins > 1.2 mg/dl) – Neurological / psychiatric diseases – HIV Infection – Active Hepatitis B or C – Melanoma or Melanoma occurrence in the family history – Non-compliance – Subjects who are legally detained in an official institution

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Charite University, Berlin, Germany
  • Provider of Information About this Clinical Study
    • Principal Investigator: PD Dr. Susanna Wiegand, Principal Investigator – Charite University, Berlin, Germany
  • Overall Contact(s)
    • Susanna Wiegand, PD Dr., +49 30 450 566887, susanna.wiegand@charite.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.